Netelenbos J C, Siregar-Emck M T, Schot L P, van Ginkel F C, Lips P, Leeuwenkamp O R
Department of Endocrinology, Academisch Ziekenhuis Vrije Universiteit, Amsterdam, Netherlands.
Maturitas. 1991 Jun;13(2):137-49. doi: 10.1016/0378-5122(91)90097-a.
The effects of 8 weeks of daily oral treatment with 1 mg 17 beta-oestradiol (E2), 2.5 mg Org OD 14 [7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) , a steroid with weak androgenic, weak oestrogenic and weak progestational activity, or placebo on calcium and lipid metabolism were compared in 21 healthy, early post-menopausal women in a randomised double-blind study. The treatment period was followed by a treatment-free period of 8 weeks to study the reversibility of drug-induced effects. The results show that both E2 and Org OD 14 reduce bone resorption, as indicated by the decreases in the urinary hydroxyproline/creatinine and calcium/creatinine ratios in 2-h fasting urine. In contrast to E2, Org OD 14 did not reduce serum calcium levels. As regards lipid parameters, E2 reduced the concentration of serum cholesterol and Org OD 14 decreased serum levels of high-density-lipoprotein cholesterol and triglycerides. All these effects appeared to be reversible after cessation of treatment. It is concluded that both of these steroids reduce bone resorption in early post-menopausal women, but that their mechanisms of action are most likely different.
在一项随机双盲研究中，对21名健康的绝经早期妇女比较了每日口服1毫克17β-雌二醇（E2）、2.5毫克Org OD 14[（7α，17α）-17-羟基-7-甲基-19-去甲孕-5（10）-烯-20-炔-3-酮，一种具有弱雄激素活性、弱雌激素活性和弱孕激素活性的甾体]或安慰剂8周对钙和脂质代谢的影响。治疗期之后是为期8周的无治疗期，以研究药物诱导效应的可逆性。结果表明，E2和Org OD 14均降低骨吸收，这由2小时空腹尿中尿羟脯氨酸/肌酐和钙/肌酐比值降低所表明。与E2不同，Org OD 14未降低血清钙水平。关于脂质参数，E2降低血清胆固醇浓度，Org OD 14降低血清高密度脂蛋白胆固醇和甘油三酯水平。所有这些效应在停止治疗后似乎都是可逆的。结论是，这两种甾体均降低绝经早期妇女的骨吸收，但它们的作用机制很可能不同。
